The ORlistat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORliCARDIA) study
Triantafyllos Didangelos, Dimitrios T. Karamitsos(Aristotle University of Thessaloniki), Kostantina Dimitriou(General Hospital of Nikea), Christos Sambanis(Aristotle University of Thessaloniki), B. Karamanos, Vasilios G. Athyros(Neurosciences Institute), Stavros Pappas(General Hospital of Nikea), Stavros Bousboulas(General Hospital of Nikea), Elefteria Spanou(National and Kapodistrian University of Athens), Anastasia Thanopoulou(National and Kapodistrian University of Athens)
Cited by 70
Related Papers
Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis
|Nutrients|2019|475
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
|Diabetes Care|2019|442
Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation
|Nutrition Reviews|2017|414
Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
|Archives of Medical Science|2015|383